<unk>  is an antineoplastic agent that is FDA approved for the treatment of patients with castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastatic disease.   Common adverse reactions include nausea, diarrhea, vomiting, and peripheral edema.
Radium-223 chloride
Lutetium Lu 177 dotatate
Technetium 
Strontium ranelate
Samarium-153-ethylene diamine tetramethylene phosphonate
Strontium chloride
Technetium-99m
Dihydroxialumini sodium carbonate